People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Harmony Biosciences II, Inc. | — | Pharmaceuticals | Series D+ | $345.0M | $1.8B | 2019 |
| T0.Com, Inc. | — | Other Technology | Series C | $122.8M | $773.7M | 2022 |
| NewType Group, Inc. | — | Other Technology | Pre-Seed | $1.1M | $1.9M | 2023 |
JOHN JACOBS at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside JOHN JACOBS on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Antonio Gracias | 1 | 15 |
| Jack Nielsen | 1 | 13 |
| Christopher Campbell | 1 | 8 |
| Aaron Royston | 1 | 7 |
| Patrick Morris | 1 | 6 |
| Jeffrey Aronin | 1 | 6 |
| Martin Edwards | 1 | 5 |
| Darien Parhad | 1 | 4 |
| Chris Campbell | 1 | 4 |
| Juan Sabater | 1 | 4 |
| Patrick Byrne | 1 | 4 |
| Matt Mosman | 1 | 4 |
| Barclay F. Corbus | 1 | 3 |
| Amit Goyal | 1 | 2 |
| Joseph Cammarata | 1 | 2 |
| Jonathan E. Johnson III | 1 | 2 |
| PETE AGTUCA | 1 | 1 |
| CASSA HANON | 1 | 1 |
| JAYSON CASTILLO | 1 | 1 |
| DAVE RANKIN | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.